· updated
Is BPC-157 Legal in 2026? The Honest, Current Answer
Update, Oct 30, 2026: in a notice filed Oct 28, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding BPC-157 under set conditions, including a patient-specific prescription. BPC-157 is still unapproved and still not on the 503A Bulks List. Read the HHS policy breakdown.
The short answer
As of this article’s publish date, BPC-157 is neither an FDA-approved drug nor a substance banned outright. It sits in a regulatory gray zone: it’s no longer on the FDA’s “restricted for compounding” list, but it also hasn’t been formally cleared for pharmacy compounding either. The only route that looks like a legitimate, provider-supervised path is a prescription from a licensed provider filled by a compliant compounding pharmacy — and even that path is currently under review. Here’s the actual timeline behind that answer.
Key facts
- Not approved: BPC-157 has never been approved by the FDA for any use.
- Category 2: added to FDA’s restricted list in September 2023; removed on April 23, 2026.
- PCAC vote: on July 23, 2026 the advisory committee voted 8-6 (1 abstention) to recommend it for the 503A Bulks List. The vote is advisory.
- Rulemaking: as of October 29, 2026, the FDA had not proposed adding it to the list.
- Interim policy: filed October 28, 2026, HHS’s enforcement discretion policy covers BPC-157 compounded under set conditions. It is not approval and it is not binding.
- Not a supplement: it is not a legal over-the-counter supplement.
The distinction people get wrong
Headlines love to say BPC-157 is “legal now” or still “banned.” Both are oversimplified. Three separate things are in play:
- FDA drug approval — BPC-157 has never gone through this process for any use. It is not an approved medicine.
- Category 2 (restricted bulk substances) — a list of substances the FDA says compounding pharmacies should not use due to safety concerns. BPC-157 was added to this list in September 2023.
- The 503A Bulks List (Category 1) — the list that affirmatively clears a substance for compounding. BPC-157 has never been on it.
In April 2026, BPC-157 came off Category 2 following the withdrawal of its restriction nomination. That removed a red flag — it did not add a green light. It’s a gray zone, not a clearance.
The dated timeline
- Sept 2023 — BPC-157 added to FDA’s Category 2 restricted bulk drug substances list.
- Feb 27, 2026 — HHS signals a policy direction toward loosening peptide restrictions generally (a direction, not a rule).
- Apr 15, 2026 — FDA formally updates the 503A list; 12 peptides removed from Category 2.
- Apr 23, 2026 — BPC-157 specifically comes off Category 2.
- Jul 23, 2026 — FDA’s Pharmacy Compounding Advisory Committee (PCAC) discusses BPC-157 (along with KPV, TB-500, and MOTS-c) for possible inclusion on the 503A Bulks List. FDA’s own pre-meeting briefing materials reportedly lean against adding it, citing adverse-event reports and a lack of human safety and effectiveness data. The committee nevertheless voted 8-6 (1 abstention) to recommend BPC-157 for the list.
- As of Oct 7, 2026: no FDA proposed rule has been published in the Federal Register; formal rulemaking could run into 2027 or longer.
- Oct 28, 2026: HHS files an interim enforcement discretion policy covering BPC-157 and five other peptides, with publication set for Oct 30.
A PCAC recommendation isn’t a final decision — FDA rules on it separately, on its own timeline, after the meeting.
So what can you actually do right now?
- It is not a legal over-the-counter supplement, and it is not sold as one by any legitimate pharmacy.
- The only pathway that resembles legitimate medical access is a prescription from a licensed provider, filled by a licensed compounding pharmacy — and that pathway’s long-term footing depends on how FDA rules after the July PCAC review.
- “Research chemical” vendors selling BPC-157 outside that pathway are not operating in a regulated, quality-controlled supply chain, regardless of what FDA ultimately decides. That’s a sourcing risk independent of the legal question.
- This is general information, not legal advice — rules can shift quickly, and your specific situation may involve state-level considerations a licensed provider is better positioned to walk through with you.
For the full picture of what’s being reviewed and why, see our breakdown of the July 2026 PCAC meeting, and check the live legal status tracker for the current status of BPC-157 and other peptides.
Frequently asked questions
Is BPC-157 FDA-approved?
No. BPC-157 has never gone through the FDA approval process for any use, so it is not an approved medicine.
Is BPC-157 on the 503A Bulks List now?
Not yet. The PCAC recommended it on July 23, 2026, but that vote is advisory, and the FDA still has to complete notice-and-comment rulemaking; as of October 29, 2026, it had not proposed adding BPC-157. HHS’s interim policy, filed October 28, is enforcement discretion and does not put it on the list.
Can you buy BPC-157 as a legal supplement?
No. It is not a legal over-the-counter supplement, and “research chemical” vendors operate outside a regulated, quality-controlled supply chain. The only path that resembles legitimate access is a prescription from a licensed provider filled by a licensed compounding pharmacy.